JIJohn Isaac

John Isaac

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John Isaac has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discarded livers tested by normothermic machine perfusion in the VITTAL trial: Secondary end points and 5-year outcomes

    by Hynek Mergental, Richard W. Laing, Amanda J. Kirkham, George Clarke, Yuri L. Boteon, Darren Barton, Desley A.H. Neil, John R. Isaac, Keith J. Roberts, Manuel Abradelo, et al.

    Normothermic machine perfusion (NMP) enables pretransplant assessment of high-risk donor livers. The VITTAL trial demonstrated that 71% of the currently discarded organs could be transplanted with 100% 90-day patient and graft survivals. Here, we report secondary end points and 5-year outcomes of this prospective, open-label, phase 2 adaptive single-arm study. The patient and graft survivals at 60 months were 82% and 72%, respectively. Four patients lost their graft due to nonanastomotic biliary strictures, one caused by hepatic artery thrombosis in a liver donated following brain death, and 3 in elderly livers donated after circulatory death (DCD), which all clinically manifested within 6 months after transplantation. There were no late graft losses for other reasons. All the 4 patients who died during the study follow-up had functioning grafts. Nonanastomotic biliary strictures developed in donated after circulatory death livers that failed to produce bile with pH >7.65 and bicarbonate levels >25 mmol/L. Histological assessment in these livers revealed high bile duct injury scores characterized by arterial medial necrosis. The quality of life at 6 months significantly improved in all but 4 patients suffering from nonanastomotic biliary strictures. This first report of long-term outcomes of high-risk livers assessed by normothermic machine perfusion demonstrated excellent 5-year survival without adverse effects in all organs functioning beyond 1 year (ClinicalTrials.gov number NCT02740608).


  • Open Access

    Vein Wall Invasion Is a More Reliable Predictor of Oncological Outcomes than Vein-Related Margins after Pancreaticoduodenectomy for Early Stages of Pancreatic Ductal Adenocarcinoma

    by Manish Ahuja, Rupaly Pandé, Shafiq Chugtai, Rachel M. Brown, Owen Cain, David C. Bartlett, Bobby V. M. Dasari, Ravi Marudanayagam, Keith J. Roberts, John Isaac, et al.

    Pancreaticoduodenectomy (PD) with vein resection is the only potentially curative option for patients with pancreatic ductal adenocarcinoma (PDAC) with venous involvement. The aim of our study was to assess the oncological prognostic significance of the different variables of venous involvement in patients undergoing PD for resectable and borderline-resectable with venous-only involvement (BR-V) PDAC. We performed a retrospective analysis of prospectively acquired data over a 10-year period. Of the 372 patients included, 105 (28%) required vein resection and vein wall involvement was identified in 37% of those. A multivariable analysis failed to identify the vein-related resection margins as independent predictors for OS, DFS or LR. Vein wall tumour involvement was an independent predictor of OS (risk x1.7–2) and DFS (risk x1.9–2.2) in all models, while it replaced overall surgical margin positivity as the only parameter independently predicting LR during an analysis of separate resection margins (risk x2.4). Vein wall tumour invasion may be a more reliable predictor of oncological outcomes compared to traditionally reported parameters. Future studies should focus on possible pre-operative investigations that could identify these cases and management pathways that could yield a survival benefit, such as the use of neoadjuvant treatments.


  • Open Access

    Potential clinical utility of intraoperative fluid amylase measurement during pancreaticoduodenectomy

    by Kunal Joshi, Manuel Abradelo, David Christopher Bartlett, Nikolaos Chatzizacharias, Bobby Venkata Dasari, John Isaac, Ravi Marudanayagam, Darius Mirza, Keith Roberts, Robert Peter Sutcliffe

    Kunal Joshi, Manuel Abradelo, David Christopher Bartlett, Nikolaos Chatzizacharias, Bobby Venkata Dasari, John Isaac, Ravi Marudanayagam, Darius Mirza, Keith Roberts, Robert Peter Sutcliffe. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.22-083


  • Where Are We Now with Liver Transplantation in Neuroendocrine Neoplasms? The Place of Liver Transplantation for Grades 1 and 2 Well-Differentiated Unresectable Liver Metastatic Neuroendocrine Tumours

    by Tahir Shah, Derek M. Manas, Samuel J. Ford, Bobby V. M. Dasari, Paul Gibbs, Hema Venkataraman, Joanna Moore, Simon Hughes, Mona Elshafie, Salil Karkhanis, et al.

    Purpose of Review This review outlines the role of liver transplantation in selected patients with unresectable neuroendocrine tumour liver metastases. It discusses the international consensus on eligibility criteria and outlines the efforts taking place in the UK and Ireland to develop effective national liver transplant programmes for neuroendocrine tumour patients. Recent Findings In the early history of liver transplantation, indications included cancer metastases to the liver as well as primaries of liver origin. Often, liver transplantation was a salvage procedure. The early results were disappointing, including in patients with neuroendocrine tumours. These data discouraged the widespread adoption of liver transplantation for neuroendocrine tumour liver metastases (NET LM). A few centres persisted in performing liver transplantation for patients with NET LM and in determining parameters predictive of good outcomes. Their work has provided evidence for benefit of liver transplantation in a selected group of patients with NET LM. Summary Liver transplantation for NET LM is now accepted as a valid indication by many professional bodies, including the European Neuroendocrine Tumour Society (ENETS) and the United Network for Organ Sharing (UNOS). It is nevertheless rarely utilised. The UK and the Republic of Ireland are commencing a pilot programme of liver transplantation in selected patients. This programme will help develop the expertise and infrastructure to make liver transplantation for NET LM a routine procedure.


  • Early postoperative risk stratification in patients with pancreatic fistula after pancreaticoduodenectomy

    by Syed S. Raza, Anisa Nutu, Sarah Powell-Brett, Alessio Marchetti, Giampaolo Perri, Amanda Carvalheiro Boteon, James Hodson, Nikolaos Chatzizacharias, Bobby V. Dasari, John Isaac, et al.


  • Open Access

    Influence of middle hepatic vein resection during right or left hepatectomy on post hepatectomy outcomes

    by Anisa Nutu, Michael Wilson, Erin Ross, Kunal Joshi, Robert Sutcliffe, Keith Roberts, Ravi Marudanayagam, Paolo Muiesan, Nikolaos Chatzizacharias, Darius Mirza, et al.

    Anisa Nutu, Michael Wilson, Erin Ross, Kunal Joshi, Robert Sutcliffe, Keith Roberts, Ravi Marudanayagam, Paolo Muiesan, Nikolaos Chatzizacharias, Darius Mirza, John Isaac, Bobby V. M. Dasari. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.21-159


  • Open Access

    Setting up a surgical complex gallstone service in a non-HPB unit

    by Siobhan Mckay, Jonathan Super, Ravi Marudanayagam, Markos Daskalakis, Rajwinder Nijjar, John Isaac, Martin Richardson, Rishi Singhal

    Objective: Complex gallstone disease is associated with a higher risk of complication during laparoscopic cholecystectomy than biliary colic and simple cholecystitis. It is traditionally managed in a hepatopancreaticobiliary (HPB) unit where there is expertise for common bile duct exploration and repair. We developed a mentorship scheme for a busy upper gastro-intestinal (UGI) unit, with support from a specialist HPB unit to treat complex gallstone disease, to reduce the burden on the HPB unit and enable local treatment of patients. Material and Methods: Through the creation of a service level agreement, the specialist HPB unit were commissioned to provide mentorship for two surgeons at a large UGI unit with an interest in providing a complex gallstone service to their local population. Eight sessions of mentored operating were supported, with the provision for additional support if complications occurred. Results: There were 14 patients included in the mentorship phase of the programme from November 2015 to May 2017. Cholecystectomies were performed on patients with previously complex histories, which included: previous cholecystostomy; CBD stones and multiple ERCPs; suspected choledochoduodenal fistula; suspected cholecystoduodenal fistula; suspected Mirrizzi’s syndrome; previous significant intra-abdominal operation; and significant medical co-morbidities. There was one post-operative complication requiring a return to theatre, and one minor wound infection associated with the complex gallstone lists. Conclusion: We demonstrated a method to reduce the burden on specialist HPB unit for the operative management of complex gallstone disease and safely implement such a service at large UGI unit with an interest in providing a complex gallstone service.

  • Outcomes of normothermic machine perfusion of liver grafts in repeat liver transplantation (NAPLES initiative)

    by A. Hann, H. Lembach, A. Nutu, B. Dassanayake, S. Tillakaratne, S. C. McKay, A. P. C. S. Boteon, Y. L. Boteon, H. Mergental, N. Murphy, et al.

    Background: Retransplantation candidates are disadvantaged owing to lack of good-quality liver grafts. Strategies that can facilitate transplantation of suboptimal grafts into retransplant candidates require investigation. The aim was to determine whether late liver retransplantation can be performed safely with suboptimal grafts, following normothermic machine perfusion. Methods: A prospectively enrolled group of patients who required liver retransplantation received a suboptimal graft preserved via normothermic machine perfusion. This group was compared with both historical and contemporaneous cohorts of patient who received grafts preserved by cold storage. The primary outcome was 6-month graft and patient survival. Results: The normothermic machine perfusion group comprised 26 patients. The historical (cold storage 1) and contemporaneous (cold storage 2) groups comprised 31 and 25 patients respectively. The 6-month graft survival rate did not differ between groups (cold storage 1, 27 of 31, cold storage 2, 22 of 25; normothermic machine perfusion, 22 of 26; P = 0.934). This was despite the normothermic machine perfusion group having significantly more steatotic grafts (8 of 31, 7 of 25, and 14 of 26 respectively; P = 0.006) and grafts previously declined by at least one other transplant centre (5 of 31, 9 of 25, and 21 of 26; P < 0.001). Conclusion: In liver retransplantation, normothermic machine perfusion can safely expand graft options without compromising short-term outcomes.


  • Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent

    by Joseph A. Attard, Alexia Farrugia, Adithya Pathanki, Keith J. Roberts, Bobby Dasari, John Isaac, Yuk Ting Ma, Nikolaos A. MD Chatzizacharias

    Historically, locally advanced pancreatic adenocarcinoma (LAPDAC) was considered a palliative condition. Advances in treatment have resulted in studies reporting survival after neoadjuvant treatment and surgery similar to earlier disease stages. However, there is no consensus on optimal LAPDAC management. Our aim was a systematic review of published evidence on LAPDAC treatment strategies with curative intent. Twenty-eight studies defining LAPDAC as per established criteria and reporting outcomes after neoadjuvant treatment with a view to resection were included. Primary outcomes were resection rate and proportion of curative resections. Secondary outcomes were postoperative mortality, progression-free survival, and overall survival. Neoadjuvant treatment varied significantly, most common being the combination of folinic acid, fluorouracil, irontecan, and oxaliplatin. Median percentage of patients proceeding to surgery after completion of neoadjuvant pathway was 33.5%. Median resection rate was 25%. Median R0 resection was 80% of resected patients. These outcomes ranged 0% to 100% across studies. Ninety-day postoperative mortality ranged from 0% to 5%. Median progression-free and overall survival for resected patients were 12.9 and 30 months, respectively, versus 13.2 months overall survival for unresected patients. In conclusion, although there is wide variability in reported LAPDAC resection rates post–neoadjuvant chemotherapy, retrospective data suggest that neoadjuvant treatment followed by surgery results in improved survival.


  • Miscellaneous problems

    by John Isaac, Mark Stoneham, Nerida Williams, Bruce McCormick

    The penultimate chapter covers miscellaneous topics not described elsewhere. Major haemorrhage is addressed with sections on controlling haemorrhage, using blood products, and diagnosing/treating acute transfusion reactions. Guidance is given for treating patients with burns, extravasation of anaesthetic agents, intra-arterial injection, inoculation injury, and bone cement implantation syndrome. Advice is presented for managing fire in theatre. Clinical guidance/recipes are given for anaesthetising patients who have bled after tonsillectomy, thyroid surgery, or carotid endarterectomy. The final two sections concern patients undergoing emergency laparotomy or emergency aortic aneurysm repair. Each problem is addressed by firstly its definitions, presentation, investigations, risk factors, and exclusions; then how it can be managed in the immediate, medium-, and long-term situations. Finally, any special considerations are outlined, followed by a list of further reading.